NOVOCURE LTD (NVCR) Stock Price, Quote, News and Overview
NASDAQ:NVCR - Nasdaq - JE00BYSS4X48 - Common Stock - Currency: USD
NVCR Quote, Performance and Key Statistics
22.09
+0.44 (+2.03%)
The current stock price of NVCR is 22.09 USD. In the past month the price decreased by -18.25%. In the past year, price increased by 45.14%.
NVCR Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 28.89 | 234.01B | ||
| ISRG | INTUITIVE SURGICAL INC | 80.74 | 211.07B | ||
| BSX | BOSTON SCIENTIFIC CORP | 41.63 | 154.00B | ||
| SYK | STRYKER CORP | 31.4 | 145.92B | ||
| MDT | MEDTRONIC PLC | 16.84 | 115.33B | ||
| BDX | BECTON DICKINSON AND CO | 16.35 | 65.30B | ||
| EW | EDWARDS LIFESCIENCES CORP | 27.98 | 43.23B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 20.29 | 41.62B | ||
| IDXX | IDEXX LABORATORIES INC | 40.25 | 37.07B | ||
| DXCM | DEXCOM INC | 53.81 | 34.68B | ||
| RMD | RESMED INC | 26.21 | 34.03B | ||
| PHG | KONINKLIJKE PHILIPS NVR- NY | 17.5 | 24.02B |
Related stock screener links
About NVCR
Company Profile
NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. The company is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. The company also has a license to market Optune in China, Hong Kong, Macau and Taiwan. The company has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.
Company Info
NOVOCURE LTD
No. 4 The Forum, Grenville Street
Saint Helier JE2 4UF JE
CEO: Asaf Danziger
Employees: 1453
Company Website: https://www.novocure.com/
Investor Relations: https://www.novocure.com/investor-relations/
Phone: 441534756700
NOVOCURE LTD / NVCR FAQ
What is the stock price of NOVOCURE LTD today?
The current stock price of NVCR is 22.09 USD. The price increased by 2.03% in the last trading session.
What is the ticker symbol for NOVOCURE LTD stock?
The exchange symbol of NOVOCURE LTD is NVCR and it is listed on the Nasdaq exchange.
On which exchange is NVCR stock listed?
NVCR stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NOVOCURE LTD stock?
13 analysts have analysed NVCR and the average price target is 37.45 USD. This implies a price increase of 69.53% is expected in the next year compared to the current price of 22.09. Check the NOVOCURE LTD stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NOVOCURE LTD worth?
NOVOCURE LTD (NVCR) has a market capitalization of 2.39B USD. This makes NVCR a Mid Cap stock.
How many employees does NOVOCURE LTD have?
NOVOCURE LTD (NVCR) currently has 1453 employees.
What are the support and resistance levels for NOVOCURE LTD (NVCR) stock?
NOVOCURE LTD (NVCR) has a support level at 22.08 and a resistance level at 22.48. Check the full technical report for a detailed analysis of NVCR support and resistance levels.
Is NOVOCURE LTD (NVCR) expected to grow?
The Revenue of NOVOCURE LTD (NVCR) is expected to grow by 18.18% in the next year. Check the estimates tab for more information on the NVCR EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NOVOCURE LTD (NVCR) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NVCR, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NVCR, evaluating the profitability, health, valuation and growth aspects
- NOVOCURE LTD (NVCR) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NOVOCURE LTD (NVCR) Sales and EPS estimates to see what analysts future expectations are.
- NOVOCURE LTD (NVCR) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NOVOCURE LTD (NVCR) Insider and Institutional Ownership to learn about the owners and their transactions.
- NOVOCURE LTD (NVCR) Stock Chart to make your own analysis
- NOVOCURE LTD (NVCR) Latest news and press-releases to stay up to date.
Does NOVOCURE LTD (NVCR) stock pay dividends?
NVCR does not pay a dividend.
When does NOVOCURE LTD (NVCR) report earnings?
NOVOCURE LTD (NVCR) will report earnings on 2025-02-27, after the market close.
What is the Price/Earnings (PE) ratio of NOVOCURE LTD (NVCR)?
NOVOCURE LTD (NVCR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.4).
What is the Short Interest ratio of NOVOCURE LTD (NVCR) stock?
The outstanding short interest for NOVOCURE LTD (NVCR) is 5.1% of its float. Check the ownership tab for more information on the NVCR short interest.
NVCR Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to NVCR. When comparing the yearly performance of all stocks, NVCR is one of the better performing stocks in the market, outperforming 91.79% of all stocks.
NVCR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVCR. NVCR may be in some trouble as it scores bad on both profitability and health.
NVCR Financial Highlights
Over the last trailing twelve months NVCR reported a non-GAAP Earnings per Share(EPS) of -1.4. The EPS increased by 24.73% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -12.26% | ||
| ROE | -41.52% | ||
| Debt/Equity | 1.81 |
NVCR Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to NVCR. The Buy consensus is the average rating of analysts ratings from 13 analysts.
For the next year, analysts expect an EPS growth of 32.92% and a revenue growth 18.18% for NVCR